SIGNUPABOUTBW_CONTENTSBW_+!DAILY_BRIEFINGSEARCHCONTACT_US


SIR RICHARD B. SYKES

As patents for its Glaxo Holdings' blockbuster antiulcer drug, Zantac, began to expire in 1995, the prognosis looked grim. But with bold strokes such as the $14 billion acquisition of Wellcome, CEO SIR RICHARD B. SYKES has kept the British drug giant healthy. Even as Zantac sales slid, Glaxo's 1996 revenues grew some 5%, to $13.9 billion. 1997 could be rough, but upcoming AIDS and flu treatments should be big hits down the road.




RELATED ITEMS

PHOTO: Sir Richard Sykes, CEO Glaxo Wellcome


Updated June 15, 1997 by bwwebmaster
Copyright 1997, Bloomberg L.P.
Terms of Use